Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Barinthus Biotherapeutics plc (BRNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: BRNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.7% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.95M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 3 | Beta -0.77 | 52 Weeks Range 0.64 - 1.58 | Updated Date 06/30/2025 |
52 Weeks Range 0.64 - 1.58 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -332.22% |
Management Effectiveness
Return on Assets (TTM) -18.2% | Return on Equity (TTM) -45.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -50248115 | Price to Sales(TTM) 2.47 |
Enterprise Value -50248115 | Price to Sales(TTM) 2.47 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -6.67 | Shares Outstanding 40339400 | Shares Floating 35027907 |
Shares Outstanding 40339400 | Shares Floating 35027907 | ||
Percent Insiders 14.45 | Percent Institutions 44.67 |
Analyst Ratings
Rating 2 | Target Price 4.5 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Barinthus Biotherapeutics plc
Company Overview
History and Background
Barinthus Biotherapeutics plc (BRNS), formerly known as Vaccitech plc, is a biopharmaceutical company founded in 2010, spun out from Oxford University. It focuses on developing novel immunotherapeutic products and vaccines for infectious diseases and cancer. Key milestones include securing funding rounds, advancing clinical trials, and strategic partnerships. The company rebranded to Barinthus Biotherapeutics in 2024 to reflect its broader therapeutic focus.
Core Business Areas
- Infectious Diseases: Developing vaccines and immunotherapies against infectious diseases, including chronic hepatitis B and shingles.
- Oncology: Developing novel cancer immunotherapies, primarily focusing on T-cell stimulation to target tumors.
Leadership and Structure
Bill Enright serves as the Chief Executive Officer. The company operates with a typical structure of a biopharmaceutical company, including research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- VTP-300 (Chronic Hepatitis B): An immunotherapeutic designed to induce immune responses against hepatitis B virus. Currently in Phase 2b clinical trials. Competitors include Gilead Sciences (GILD) and Vir Biotechnology (VIR). No specific market share data available yet.
- VTP-850 (Prostate Cancer): A cancer vaccine designed to target prostate cancer. Currently in Phase 1/2 clinical trials. Competitors include companies developing other cancer vaccines and immunotherapies such as Moderna (MRNA) and BioNTech (BNTX). No specific market share data available yet.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The sector is driven by innovation and unmet medical needs.
Positioning
Barinthus Biotherapeutics is a clinical-stage company with a focus on developing novel immunotherapies. Its competitive advantage lies in its proprietary platform technology and expertise in T-cell stimulation.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is projected to reach USD 4.8 billion by 2030. The cancer vaccine market is expected to reach USD 14.8 billion by 2030. Barinthus Biotherapeutics is positioned to capture a segment of these markets with its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Proprietary platform technology
- Strong scientific team
- Promising clinical trial results
- Strategic collaborations with leading institutions
Weaknesses
- Limited financial resources compared to larger competitors
- Clinical trial risks and uncertainties
- Dependence on successful development of pipeline candidates
- No products currently generating revenue
Opportunities
- Potential for breakthrough therapies in areas of unmet need
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Favorable regulatory environment for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- GILD
- VIR
- MRNA
- BNTX
Competitive Landscape
Barinthus Biotherapeutics competes with larger, more established pharmaceutical companies. Its advantage lies in its novel approach and expertise in T-cell stimulation. Disadvantages include limited financial resources and the risks associated with clinical-stage development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of pipeline candidates through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of products. Analyst estimates vary widely depending on the success of the pipeline.
Recent Initiatives: Recent initiatives include the initiation of new clinical trials, strategic partnerships, and strengthening the intellectual property portfolio.
Summary
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of immunotherapies and vaccines. It's currently not strong with no products commercially available. The company's expertise in T-cell stimulation and strategic partnerships are working well to advance clinical trials. Barinthus needs to monitor clinical trial outcomes and competition from larger companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Barinthus Biotherapeutics plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-04-30 | CEO, Director & Principal Financial Officer Mr. William J. Enright MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.barinthusbio.com |
Full time employees 105 | Website https://www.barinthusbio.com | ||
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.